Lucid Diagnostics Inc
Veridion Score
Composite trend over time
Why is LUCD moving today?
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LUCD.
LUCD insider activity
Lucid Diagnostics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $347K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | 2026-05-20 | Matheis Dennis | Insider | buy | $1.00 | 245,000 | 1,033,443 | $245K | SEC Form 4 |
| 2025-08-22 | 2025-08-20 | Matheis Dennis | Insider | buy | $1.02 | 100,000 | 665,443 | $102K | SEC Form 4 |
LUCD contract awards, year to date.
Public federal awards linked to this ticker.
LUCD lobbying filings, year to date.
Registered lobbying filings matched to Lucid Diagnostics Inc.